Shlomi Madar
CEO
SpotitEarly
SpotitEarly develops an at-home, non-invasive cancer pre-screening test utilizing Volatile Organic Compounds (VOCs) detected in a single breath sample. The platform integrates canine olfactory detection with a proprietary Bio-AI hybrid platform named LUCID for accurate analysis of cancer biomarkers. This technology aims to increase the adoption of early-stage cancer screening across wider populations affordably.
- Artificial Intelligence
- Biotechnology
- Digital Health
- Healthcare Technology
- Software Only
Updated 7 months ago
Funding
Raised to date
$6.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current cancer screening methods often involve invasive procedures, specialized equipment, and clinic visits, limiting accessibility and adherence, especially for early detection when treatment is most effective. Traditional single-cancer screening approaches also require multiple tests, increasing costs and patient burden.
Solution
SpotitEarly offers a non-invasive, at-home breath test for pre-screening multiple cancer types simultaneously. The technology uses scent-based bio-detectors to identify volatile organic compounds (VOCs) present in exhaled breath, which serve as biomarkers for various cancers. An AI-driven platform, LUCID, analyzes the data collected by the biosensors, increasing the accuracy of the results. This approach aims to make cancer pre-screening more accessible, affordable, and convenient, enabling earlier detection and improved clinical outcomes.
Target Audience
The primary target audience includes individuals seeking convenient and accessible cancer pre-screening options, healthcare providers aiming to improve early detection rates, and organizations focused on expanding cancer screening programs to broader populations.
Features
- At-home breath collection kit for easy sample acquisition
- Scent-based bio-detectors that identify cancer-specific VOCs in breath samples
- LUCID, an AI platform that analyzes biosensor data to enhance accuracy
- Capability to pre-screen for multiple cancer types (breast, lung, colorectal, prostate) with a single test
- High sensitivity and specificity (94% in early-stage cancer, according to clinical trials)
- Online prescription service, eliminating the need for in-person appointments